American Bioanalytical Receives ISO 13485:2003 Certification

American Bioanalytical Inc., a leading supplier of high quality biochemicals and reagent products for life science research and manufacturing applications, announced today they received ISO 13485:2003 Certification. The ISO 13485:2003 Certification is an internationally recognized quality standard designed to ensure that medical device manufacturers have the required quality management systems in place to safely design, manufacture and distribute medical devices. In addition to this new Certification, the company previously achieved their ISO 9001:2008 Certification.

“The mission of American Bioanalytical is to offer the highest quality components, solutions and reagent products to our clients and ISO 13485:2003 and ISO 9001:2008 certifications help support that commitment” stated Wayne Gagnon, Vice President of American Bioanalytical. Gagnon continues, “Achieving these certificates validates our commitment to quality and strengthens our ability to compete in this global marketplace."

The certificate validates American Bioanalytical’s solid design control and quality management systems their clients have come to rely on and will help comply with increased industry expectations for quality. Their clients are focused on improving human health through basic research, development of molecular diagnostic applications and personalized medicines.

About American Bioanalytical

American Bioanalytical, Inc. (www.americanbio.com) founded in 1977, is a Natick, MA based company and a leading supplier of high quality biochemicals and reagent products for life science research and manufacturing applications. American Bioanalytical offers more than 350 biochemicals and reagents used in life science research applications. American Bioanalytical has been a part of significant milestones in life science history, from our early days of providing high quality biochemicals and reagents to basic research institutions to providing key raw materials to the Human Genome Project, to our work in the development of next generation sequencing solutions, to our position as a provider of biochemicals and reagents to emerging biopharmaceutical and molecular diagnostic companies, we have consistently met and exceeded clients expectations. For more information email Kim Panton at kim@sousacommunications.com or call 617.510.5690.